A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy. Novavax (NVAX -6.34%) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with Sanofi. Understandably, Novavax's share price leaped on news of the potentially lucrative deal with the global pharmaceutical sector company. This has left the stock fairly valued, in the opinion of one analyst tracki ...